Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
Conditions
Interventions
KHK4951
Aflibercept Injection
Locations
84
United States
Barnet Dulaney Perkins Eye Center - Phoenix
Mesa, Arizona, United States
Retina Associates Southwest, P.C.
Tucson, Arizona, United States
Win Retina
Arcadia, California, United States
Retina Vitreous Associates Medical Group
Beverly Hills, California, United States
The Retina Partners
Encino, California, United States
Salehi Retina Institute, Inc
Huntington Beach, California, United States
Start Date
January 31, 2024
Primary Completion Date
August 31, 2026
Completion Date
September 30, 2026
Last Updated
October 30, 2025
NCT07308639
NCT06929143
NCT06075147
NCT04514653
NCT07481500
NCT06817915
Lead Sponsor
Kyowa Kirin Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions